FDA warns Turkish OTC drug maker Tan Alize over missing glycerin identity testing and a weak quality unit; import alert issued.
What happened
FDA reviewed records the firm sent in response to an April 13, 2023 request for records under section 704(a)(4) of the FD&C Act (a written demand for documents, not an inspection). The records showed the firm did not test each incoming lot of high-risk components such as glycerin for identity, including the USP test that detects diethylene glycol (DEG) and ethylene glycol (EG). FDA also found the quality unit did not use its authority to approve or reject components. FDA placed the firm on Import Alert 66-40 on June 23, 2023.
What FDA found
The firm did not run at least one identity test on each shipment of each lot of incoming ingredients, including glycerin and other components at high risk of DEG or EG contamination.
21 CFR 211.84(d)(1)The quality unit did not effectively use its responsibility and authority to approve or reject components, containers, closures, and other materials.
21 CFR 211.22(a)
What FDA wants
FDA asks the firm to reply in writing within 30 working days describing corrections, and to send DEG and EG test results within 30 calendar days plus a risk assessment covering products still within expiry, with customer notifications and recalls if any lot is contaminated. FDA also recommends hiring a qualified CGMP consultant to audit the whole operation.
Who should pay attention
- brands and distributors that buy OTC drug products from this Turkish manufacturer
- US importers of OTC drugs and sunscreens
- quality teams at any drug maker using glycerin or other high-risk components
This is a summary. Read the original letter on fda.gov.